30 related articles for article (PubMed ID: 8034435)
1. Clinical review: use of vancomycin in haemodialysis patients.
Launay-Vacher V; Izzedine H; Mercadal L; Deray G
Crit Care; 2002 Aug; 6(4):313-6. PubMed ID: 12225605
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin clearance with high-flux dialysis membranes.
Anandan JV; Touchette MA
Int J Artif Organs; 1998 Mar; 21(3):131-3. PubMed ID: 9622110
[No Abstract] [Full Text] [Related]
3. Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.
MacLeod A; Daly C; Khan I; Vale L; Campbell M; Wallace S; Cody J; Donaldson C; Grant A
Cochrane Database Syst Rev; 2001; (3):CD003234. PubMed ID: 11687058
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of three haemodialysis membranes on vancomycin disposition.
Alwakeel J; Najjar TA; al-Yamani MJ; Huraib S; al-Haider A; Abu-aisha H
Int Urol Nephrol; 1994; 26(2):223-8. PubMed ID: 8034435
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.
DeSoi CA; Sahm DF; Umans JG
Am J Kidney Dis; 1992 Oct; 20(4):354-60. PubMed ID: 1415203
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile.
Torras J; Cao C; Rivas MC; Cano M; Fernandez E; Montoliu J
Clin Nephrol; 1991 Jul; 36(1):35-41. PubMed ID: 1889149
[TBL] [Abstract][Full Text] [Related]
7. [The effect of hemodialysis with frequent use of cuprophan and polysulfone membranes on activation of complement in patients with chronic renal failure].
Zukowska-Szczechowska E; Moczulski D; Grzeszczak W; Gosek K; Augustyn M; Staszewicz P
Pol Arch Med Wewn; 1996 Nov; 96(5):458-68. PubMed ID: 9091856
[TBL] [Abstract][Full Text] [Related]
8. The influence of cuprophan and polysulfone membranes on dialyzer reusability and intradialytic complications.
Kadiri S; Kehinde Z; Arije A; Salako BL
Afr J Med Med Sci; 2001 Sep; 30(3):191-4. PubMed ID: 14510127
[TBL] [Abstract][Full Text] [Related]
9. Platelet-neutrophil interactions during hemodialysis: a proposed biocompatibility approach.
Stuard S; Bonomini M; Settefrati N; Albertazzi A
Int J Artif Organs; 1998 Feb; 21(2):75-82. PubMed ID: 9569128
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vancomycin in anuria.
Cunha BA; Quintiliani R; Deglin JM; Izard MW; Nightingale CH
Rev Infect Dis; 1981; 3 suppl():S269-72. PubMed ID: 7342290
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients.
Bierman MH; Needham-Walker CA; Hammeke M; Egan JD
J Dial; 1980; 4(4):179-84. PubMed ID: 7204716
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of vancomycin in patients with various degrees of renal function.
Matzke GR; McGory RW; Halstenson CE; Keane WF
Antimicrob Agents Chemother; 1984 Apr; 25(4):433-7. PubMed ID: 6732213
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia.
Masur H; Francioli P; Ruddy M; Murray HW
Clin Nephrol; 1983 Aug; 20(2):85-8. PubMed ID: 6616979
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.
Eykyn S; Phillips I; Evans J
Br Med J; 1970 Jul; 3(5714):80-2. PubMed ID: 5428782
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of vancomycin.
Matzke GR; Zhanel GG; Guay DR
Clin Pharmacokinet; 1986; 11(4):257-82. PubMed ID: 3530582
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
